Susan Haigney

The companies have restructured their existing collaboration into a licensing agreement that invests in mRNA development.

CDMOs and CMOs will continue to invest in biopharmaceutical services and facilities as the bio/pharmaceutical industry looks to biosimilars and personalized medicine.